App-Quantinova.ai

SIRPFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages

Gloria H. Y. Lin - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Intratumoral administration of OncoVEXmGM-CSF results in local innate immune alterations and induces systemic anti-tumor effects in syngeneic mouse tumor models

Keegan Cooke - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Imlygic

The amphiphatic (2,2)-amino acid derivative, LTX-401 induces complete regression of experimental hepatocellular carcinomas

Brynjar Mauseth - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of the combination of the prodrug-mediated gene therapy vector AdV-tk and immune checkpoint inhibitor for glioblastoma treatment in a syngeneic mouse model

Maria Carmela Speranza - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ganciclovir

Combination immunotherapy: T-cell costimulation (OX40L, TL1A, 4-1BBL and ICOSL) secreted locally by Gp96-Ig vaccines, elicits robust antigen-specific, memory T cell responses and tumor elimination

George J. Fromm - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

OX40L

Cancer vaccine development for hepatocellular carcinoma - HEPAVAC

Sarah Kutscher - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

CVac

Erythrocytes used as tumor antigen delivery system to target antigen-presenting cells embody an innovative approach for in situ cancer immunotherapy

Magali Cremel - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A-337, a potent bispecific antibody targeting EpCAMCD3, as a potential immunotherapeutic agent for human solid tumors

Yumin Cui - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Novel animal models for prediction of cancer vaccine response

Heather Gibson - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

CVac

Optimizing prostate cancer immunotherapy by reducing vaccine induced PD-1 expression

Christopher D. Zahm - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Spontaneous and vaccine-induced clearance of Mus Musculus Papillomavirus1 (MusPV1) infection

Rosie T. Jiang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Checkpoint inhibitors and a multivalent melanoma vaccine as a novel combinatorial therapy

Rachana R. Maniyar - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ipilimumab

cGMP production of a chimeric virus-like particle vaccine for prevention of HPV-associated cancers

George W. Buchman - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Human papilloma virus vaccine

Multi-cell phylogenetic inference of copy number evolution in breast cancer

Alexander J. Davis - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The genetic evolution of melanoma

Alan H. Shain - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Assessing intra-tumor heterogeneity and tracking longitudinal and spatial clonal evolution by next-generation sequencing

Yuchao Jiang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reconstructing the evolutionary history of metastatic cancers

Johannes G. Reiter - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Multiclonal invasion in breast cancer identified by single cell DNA sequencing

Anna K. Casasent - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clonal evolution of skin carcinomas during tumor progression and metastasis

Melissa Q. McCreery - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tamoxifen

Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing

Poojitha N Ojamies - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Filters

41730 Abstracts